Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Texas: - Dell Seton Medical Center at The University of Texas — Austin, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- Ben Taub General Hospital — Houston, Texas
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Texas: - Houston Methodist San Jacinto Hospital — Baytown, Texas
- MD Anderson in The Woodlands — Conroe, Texas
- Houston Methodist Cypress Hospital — Cypress, Texas
- Lyndon Baines Johnson General Hospital — Houston, Texas
- Houston Methodist Hospital — Houston, Texas
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Texas: - The Don and Sybil Harrington Cancer Center — Amarillo, Texas
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Texas: - Texas Oncology-West Texas — Abilene, Texas
- Texas Oncology-Northeast Texas — Allen, Texas
- Texas Oncology-West Texas — Amarillo, Texas
- Texas Oncology - Central/South Texas — Austin, Texas
- Texas Oncology - Central South (Balcones Dr) — Austin, Texas
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Texas: - Research Site — Austin, Texas
- Research Site — Bedford, Texas
- Research Site — Dallas, Texas
- Research Site — Dallas, Texas
- Research Site — Dallas, Texas
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in Texas: - El Paso Texas Oncology — El Paso, Texas
- Kelsey Seybold Clinic — Houston, Texas
- University of Texas — Houston, Texas
- Texas Oncology P A Plano East — Plano, Texas
- Texas Oncology PA Tyler — Tyler, Texas
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Texas: - Research Site — Dallas, Texas
- Research Site — Dallas, Texas
- Research Site — Dallas, Texas
- Research Site — El Paso, Texas
- Research Site — Flower Mound, Texas
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Texas: - Texas Oncology Cancer Center — Austin, Texas
- JPS Oncology & Infusion Center — Fort Worth, Texas
- Texas Oncology - DFW — Irving, Texas
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Texas: - Texas Oncology-Dallas Presbyterian Hospital ( Site 8000) — Dallas, Texas
- Parkland Health and Hospital System ( Site 0069) — Dallas, Texas
- UT Southwestern Medical Center ( Site 0050) — Dallas, Texas
- The Center for Cancer and Blood Disorders ( Site 0041) — Fort Worth, Texas
- Texas Oncology - San Antonio ( Site 8002) — San Antonio, Texas
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Texas: - Texas Oncology - Austin — Austin, Texas
- Texas Oncology - Dallas Presbyterian Hospital — Dallas, Texas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- The University of Texas Southwestern Medical Center — Dallas, Texas
- Baylor College of Medicine - Dan L. Duncan Comprehensive Cancer Center — Houston, Texas
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Texas: - Texas Oncology - Central/South Texas — Austin, Texas
- Texas Oncology - West Texas — El Paso, Texas
- Texas Oncology - Northeast Texas — Flower Mound, Texas
- (USOR) Texas Oncology — Houston, Texas
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Texas: - Community Clinical Trials — Kingwood, Texas
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Texas: - Clinical Trial Site — Denton, Texas
- Clinical Trial Site — El Paso, Texas
- Clinical Trial Site — Houston, Texas
- Clinical Trial Site — San Antonio, Texas
Phase 3 Recruiting Academic/Other
The trial aims to investigate the use of superparamagnetic iron oxide (SPIO) nanoparticles as a tracer for delayed sentinel lymph node dissection (d-SLND) in patients where upfront axillary surgery (SLND) is oncologically deemed unnecessar…
Sponsor: Uppsala University
NCT ID: NCT04722692
Sites in Texas: - Baylor College Of Medicine — Houston, Texas
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Texas: - Hendrick Medical Center — Abilene, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Lyndon Baines Johnson General Hospital — Houston, Texas
- Houston Methodist Hospital — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the reco…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05563220
Sites in Texas: - Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- MD Anderson Cancer Center Texas — Houston, Texas
- UT Health San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Texas: - Clinical Trial Network — Houston, Texas
- Oncology and Hematology of South Texas, PA — Laredo, Texas
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Texas: - Texas Oncology — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Texas: - Mary Crowley Cancer Research Center — Dallas, Texas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- University of Texas Southwestern — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- START San Antonio — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Texas: - Texas Oncology DFW — Dallas, Texas
- The University of Texas Southwestern Medical Center — Dallas, Texas
- Texas Oncology Gulf Coast — Houston, Texas
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Texas: - Texas Oncology - West Texas — Amarillo, Texas
- Texas Oncology, P.A. — Dallas, Texas
- Texas Oncology Gulf Coast — Pearland, Texas
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
- Community Clinical Trials — Kingwood, Texas
- Tranquil Clinical Research — Webster, Texas
Phase 1, Phase 2 Recruiting Industry
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, six co…
Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in Texas: - Texas Oncology-Plano East — Plano, Texas
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas